AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Substrate Artificial Intelligence is moving forward with preparations for the initial public offering (IPO) of its subsidiary, 4D Médica. The company has proposed a preliminary valuation range of between €18 million and €25 million for the float. To support this process, Substrate AI has appointed the consultancy firm LKS Next.
LKS Next will play a crucial role in the IPO by preparing the necessary documentation, assisting with market selection, and engaging with potential stakeholders. This engagement underscores Substrate AI’s commitment to ensuring a well-managed and successful IPO for 4D Médica.
4D Médica, which is predominantly owned by Substrate AI following the acquisition of a 70% stake in 2022, has been collaborating closely with its parent company to advance its AI-driven medical imaging systems. The subsidiary has experienced substantial growth recently, with its revenue tripling from €1.8 million in 2021 and maintaining an EBITDA margin above 25%.
The company has developed a software-as-a-service (SaaS) platform that leverages artificial intelligence to enhance diagnostic imaging. This platform is designed to improve diagnostic accuracy across both veterinary and human medicine, demonstrating 4D Médica’s role in innovating medical technology through advanced AI solutions.
In its recent statement, Substrate AI highlighted the significant progress 4D Médica has made, reflecting its strong performance and market potential. The planned IPO is a strategic move aimed at further capitalizing on the subsidiary’s growth and expanding its reach in the diagnostic imaging sector.
The involvement of LKS Next is expected to streamline the IPO process, ensuring that all aspects from documentation to market engagement are handled effectively. The consultancy’s expertise will be instrumental in navigating the complexities of going public and positioning 4D Médica for success in the market.
Overall, the IPO of 4D Médica represents a key milestone for Substrate Artificial Intelligence as it continues to support and expand its portfolio of innovative AI-driven solutions. The successful execution of the IPO will not only highlight the achievements of 4D Médica but also reinforce Substrate AI’s strategic vision for growth and advancement in the field of artificial intelligence.
